Article Sidebar

PDF
Date Published: 16/06/2024
Abstract Views: 141
Views PDF: 51
DOI: https://doi.org/10.51298/vmj.v539i3.9998
Issue
Vol. 539 No. 3 (2024)
Section
Các bài báo
How to Cite
Trần , X. H., Trần , Đức H., & Nguyễn , H. T. (2024). MULTIDISCIPLINARY CONSULTATION IN TREATMENT FOR T3, UNINVOLVED CIRCUMFERENTIAL RESECTION MARGIN RECTAL CANCER. Vietnam Medical Journal, 539(3). https://doi.org/10.51298/vmj.v539i3.9998

MULTIDISCIPLINARY CONSULTATION IN TREATMENT FOR T3, UNINVOLVED CIRCUMFERENTIAL RESECTION MARGIN RECTAL CANCER

Xuân Hùng Trần 1,, Đức Huy Trần 1, Hữu Thịnh Nguyễn 1
1 University of Medicine and Pharmacy at Ho Chi Minh City

Main Article Content

Abstract

Introduction: In many centers in Vietnam, upfront surgery is often prescribed for T3 rectal adenocarcinoma, but the multidisciplinary consultation is not routinely involved, lead the treatment outcomes may not be satisfactory as expected. Methods: Longitudinal cohort study, patients who were diagnosed as rectal adenocarcinoma, stage T3a/b/c, uninvolved circumferenrial resection margin and received the multidisciplinary team consultation at the University Mecical Center from December 2021 to December 2023. Results: The rate of radical surgery performed exactly as originally planned is 95.7%. Mesorectum complete rate and involved circumferenrial resection margin rate were 96.4% and 2.9%, respectively. Conclusions: Multidisciplinary team consultation and upfront surgery for T3, uninvolved circumferenrial resection margin rectal cancer have initially brought positive outcomes.

Article Details

Keywords

Rectal cancer, circumferential resection margin, multidisciplinary team

References

1. Phạm Công Khánh. Nghiên cứu giá trị cộng hưởng từ trong chẩn đoán ưng thư trực tràng giữa và dưới được phẫu thuật triệt để. Luận án Tiến sĩ Y học. 2021.
2. Enker WE, Levi GS. Macroscopic assessment of mesorectal excision. Cancer. 2009; 115(21), 4890-4894.
3. Ferlay J, Ervik M, Lam F, et al.. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2024; Available from: https://gco.iarc.who. int/today, accessed [08 February 2024].
4. Glynne-Jones R, Wyrwicz L, Tiret E, et al.. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017; 28(4), iv22-iv40.
5. Kulu Y, Tarantino I, Billeter A T, et al.. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer. Ann Surg Oncol. 2016; 23(1), 106-113.
6. Ptok H, Meyer F, Gastinger I, et al. Multimodal Treatment of cT3 Rectal Cancer in a Prospective Multi-Center Observational Study: Can Neoadjuvant Chemoradiation Be Omitted in Patients with an MRI-Assessed, Negative Circumferential Resection Margin? Visc Med. 2021; 37(5), 410-417.
7. Valadão M, Dias JA, Araújo R, et al.. Do We Have to Treat All T3 Rectal Cancer the Same Way? Clinical Colorectal Cancer. July 2020; https://doi.org/10.1016/j.clcc.2020.07.005.
8. Zeng Z, Li Z, Luo S, et al. MRI-defined T3, clear mesorectal fascia mid-low rectal cancer: is neoadjuvant treatment necessary? J Gastroenterol Hepatol. 2024; doi:10.1111/jgh.16451.